The use of '31I-MIBG in the imaging of metastatic carcinoid tumours
1988
Using 131I-MIBG for Imaging Metastatic Carcinoid Tumours
Sample size: 11
publication
Evidence: moderate
Author Information
Author(s): D.I. Jodrell, A.T. Irvine, V.R. McCready, E. Woodcraft, I.E. Smith
Primary Institution: Royal Marsden Hospital
Hypothesis
If carcinoid tumours take up 131I-MIBG, it may be possible to use it for therapeutic doses.
Conclusion
The study found that 73% of patients with metastatic carcinoid tumours showed abnormal uptake of 131I-MIBG.
Supporting Evidence
- 73% of patients showed abnormal uptake of 131I-MIBG.
- One patient with bone metastases had no uptake of 131I-MIBG.
- No correlation was found between urinary 5HIAA levels and 131I-MIBG uptake.
Takeaway
Doctors used a special medicine to see if it could help find cancer in patients, and it worked for most of them.
Methodology
Patients received 131I-MIBG and were imaged at 24, 48, and 72 hours post-injection.
Limitations
The study could not confirm the relationship between carcinoid symptoms and 131I-MIBG uptake.
Participant Demographics
Patients aged 41-72, with a median age of 60; 5 males and 6 females.
Want to read the original?
Access the complete publication on the publisher's website